618 related articles for article (PubMed ID: 21556875)
21. Extended-spectrum beta-lactamases and clinical outcomes: current data.
Ramphal R; Ambrose PG
Clin Infect Dis; 2006 Apr; 42 Suppl 4():S164-72. PubMed ID: 16544267
[TBL] [Abstract][Full Text] [Related]
22. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
[TBL] [Abstract][Full Text] [Related]
24. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.
Kotapati S; Kuti JL; Nightingale CH; Nicolau DP
J Infect; 2005 Oct; 51(3):211-7. PubMed ID: 16230218
[TBL] [Abstract][Full Text] [Related]
25. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program.
Bhavnani SM; Ambrose PG; Craig WA; Dudley MN; Jones RN;
Diagn Microbiol Infect Dis; 2006 Mar; 54(3):231-6. PubMed ID: 16423491
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Park SY; Kang CI; Joo EJ; Ha YE; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
Microb Drug Resist; 2012 Oct; 18(5):518-24. PubMed ID: 22742454
[TBL] [Abstract][Full Text] [Related]
27. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.
Lautenbach E; Patel JB; Bilker WB; Edelstein PH; Fishman NO
Clin Infect Dis; 2001 Apr; 32(8):1162-71. PubMed ID: 11283805
[TBL] [Abstract][Full Text] [Related]
28. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
[TBL] [Abstract][Full Text] [Related]
29. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.
Paterson DL; Ko WC; Von Gottberg A; Mohapatra S; Casellas JM; Goossens H; Mulazimoglu L; Trenholme G; Klugman KP; Bonomo RA; Rice LB; Wagener MM; McCormack JG; Yu VL
Clin Infect Dis; 2004 Jul; 39(1):31-7. PubMed ID: 15206050
[TBL] [Abstract][Full Text] [Related]
30. Extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.
Shanthi M; Sekar U
J Assoc Physicians India; 2010 Dec; 58 Suppl():41-4. PubMed ID: 21568008
[TBL] [Abstract][Full Text] [Related]
31. Clinical implications, risk factors and mortality following community-onset bacteremia caused by extended-spectrum β-lactamase (ESBL) and non-ESBL producing Escherichia coli.
Hsieh CJ; Shen YH; Hwang KP
J Microbiol Immunol Infect; 2010 Jun; 43(3):240-8. PubMed ID: 21291853
[TBL] [Abstract][Full Text] [Related]
32. [Risk factors and prognosis in 31 patients with extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bloodstream infection].
Chen YH; Yao WZ; Wu R; Zhou QT; Liu ZY; Zhang XW
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):815-9. PubMed ID: 19080534
[TBL] [Abstract][Full Text] [Related]
33. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae isolated in a rural hospital.
Basak S; Mallick SK; Bose S
J Indian Med Assoc; 2009 Dec; 107(12):855-8. PubMed ID: 20509468
[TBL] [Abstract][Full Text] [Related]
34. Nosocomial bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae resistant to third-generation cephalosporins, Finland, 1999-2013: Trends, patient characteristics and mortality.
Martelius T; Jalava J; Kärki T; Möttönen T; Ollgren J; Lyytikäinen O;
Infect Dis (Lond); 2016; 48(3):229-34. PubMed ID: 26577519
[TBL] [Abstract][Full Text] [Related]
35. [Clinical analysis of nosocomial infection of extended spectrum beta-lactamase-producing bacteria].
Cao B; Wang H; Chen M
Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):581-4. PubMed ID: 11758235
[TBL] [Abstract][Full Text] [Related]
36. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.
Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
Am J Infect Control; 2007 Nov; 35(9):606-12. PubMed ID: 17980240
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
[TBL] [Abstract][Full Text] [Related]
38. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies.
Trecarichi EM; Tumbarello M; Spanu T; Caira M; Fianchi L; Chiusolo P; Fadda G; Leone G; Cauda R; Pagano L
J Infect; 2009 Apr; 58(4):299-307. PubMed ID: 19272650
[TBL] [Abstract][Full Text] [Related]
39. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection.
Hyle EP; Lipworth AD; Zaoutis TE; Nachamkin I; Bilker WB; Lautenbach E
Arch Intern Med; 2005 Jun; 165(12):1375-80. PubMed ID: 15983286
[TBL] [Abstract][Full Text] [Related]
40. [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in spanish hospitals (GEIH-BLEE Project 2002)].
Hernández JR; Pascual A; Cantón R; Martínez-Martínez L;
Enferm Infecc Microbiol Clin; 2003 Feb; 21(2):77-82. PubMed ID: 12586030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
